C-reactive protein is linked to lower cognitive performance in overweight and obese women

Inflammation

Volumn 31, Issue 3, 2008, Pages 198-207

  Sweat, V ^a   Starr, V ^a   Bruehl, H ^a   Arentoft, A ^a   Tirsi, A ^a   Javier, E ^a   Convit, A ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Cognition; CRP; Gender; Obesity; Overweight

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; ATTENTION; BODY MASS; COGNITION; FEMALE; FRONTAL LOBE; HUMAN; INTELLIGENCE QUOTIENT; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL CONCENTRATION; NEUROPSYCHOLOGICAL TEST; OBESITY; PROTEIN BLOOD LEVEL; RECALL; SCORING SYSTEM; SEX DIFFERENCE; TASK PERFORMANCE; VISUAL MEMORY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; COGNITION; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; SEX FACTORS;

EID: 43349099470     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10753-008-9065-3     Document Type: Article

References (72)

1. Lee, W.-Y., J.-S. Park, S.-Y. Noh, E.-J. Rhee, K.-C. Sung, B.-S. Kim, J.-H. Kang, S.-W. Kim, M.-H. Lee, and J.-R. Park. 2004. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int. J. Cardiol. 97:101-106.
2. Wang, Z., and W. E. Hoy. 2007. C-reactive protein and the risk of developing type 2 diabetes in Aboriginal Australians. Diabetes Res. Clin. Pract. 76:37-43.
3. Han, T., C. Gonzalez-Villalpando, N. Sattar, M. Lean, K. Williams, and S. M. Haffner. 2007. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25(11):2016-2021.
4. Pearson, T. A., G. A. Mensah, R. W. Alexander, J. L. Anderson, R. O. Cannon III, M. Criqui, Y. Y. Fadl, S. P. Fortmann, Y. Hong, G. L. Myers, N. Rifai, S. C. Smith Jr., K. Taubert, R. P. Tracy, and F. Vinicor. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3):499-511 (Jan).
5. Kushner, I., D. Rzewnicki, and D. Samols. 2006. What does minor elevation of C-reactive protein signify? Am. J. Med. 119:166.e17-166.e28.
6. Swanson, S. J., M. M. McPeek, and R. F. Mortensen. 1989. Characteristics of the binding of human C-reactive protein (CRP) to laminin. J. Cell Biochem. 40(1):121-132 (May).
7. Pepys, M. B., and M. L. Baltz. 1983. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol. 34:141-212.
8. Haffner, S. M. 2006. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol. 97(2, Supplement 1):3-11 (Jan).
9. Parikh, N. I., M. J. Pencina, T. J. Wang, K. J. Lanier, C. S. Fox, R. B. D'Agostino, and R. S. Vasan. 2007. Increasing trends in incidence of overweight and obesity over 5 decades. Am. J. Med. 120(3):242-250 (Mar).
10. Ye, X., Z. Yu, H. Li, O. H. Franco, Y. Liu, and X. Lin. 2007. Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J. Am. Coll. Cardiol. 49(17):1798-1805 (May).
11. Florez, H., S. Castillo-Florez, A. Mendez, P. Casanova-Romero, C. Larreal-Urdaneta, D. Lee, and R. Goldberg. 2006. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res. Clin. Pract. 71(1):92-100 (Jan).
12. Wasir, J. S., A. Misra, N. K. Vikram, R. M. Pandey, and K. Luthra. 2007. C-reactive protein, obesity, and insulin resistance in postmenopausal women in urban slums of North India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 1(2):83-89 (Jun).
13. Thorand, B., J. Baumert, A. Doring, C. Herder, H. Kolb, W. Rathmann, G. Giani, and W. Koenig. 2006. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 184(1):216-224 (Jan).
14. Rexrode, K. M., A. Pradhan, J. E. Manson, J. E. Buring, and P. M. Ridker. 2003. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann. Epidemiol. 13(10):674-682 (Nov).
15. Lear, S., M. Chen, C. L. Birmingham, and J. J. Frohlich. 2003. The relationship between simple anthropometric indices and C-reactive protein: ethnic and gender differences. Metabolism 52(12):1542-1546.
16. Khera, A., D. McGuire, S. Murphy, H. Stanek, S. Das, W. Vongpatanasin, F. Wians, S. Grundy, and J. de Lemos. 2005. Race and gender differences in C-reactive protein levels. J. Am. Coll. Cardiol. 46(3):464-469.
17. Pieroni, L., J. P. Bastard, A. Piton, L. Kalil, B. Hainique, and C. Jardel. 2003. Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. Diabetes Metab. 29:133-138.
18. Kraus, V. B., T. V. Stabler, G. Luta, J. B. Renner, A. D. Dragomir, and J. M. Jordan. 2007. Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarth. Cartil. 15(8):966-971 (Aug).
19. Lakoski, S., M. Cushman, M. Criqui, T. Rundek, R. Blumenthal, R. B. D'Agostino, and D. Herrington. 2006. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am. Heart J. 152(3):593-598.
20. Kluft, C. 2002. HRT effects on inflammatory markers: is chronic inflammation a contra-indication for HRT? Int. Congr. Ser. 1229:103-108.
21. Abdullah, S. M., A. Khera, D. Leonard, S. R. Das, R. M. Canham, S. A. Kamath, G. L. Vega, S. M. Grundy, D. K. McGuire, and J. A. de Lemos. 2007. Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. Atherosclerosis 195(2):404-410 (Dec).
22. Ferrannini, E., A. Natali, P. Bell, P. Cavallo-Perin, N. Lalic, and G. Mingrone. 1997. Insulin resistance and hypersecretion in obesity. J. Clin. Invest. 100(5):1166-1173 (Sep).
23. Smith, D. O., and D. LeRoith. 2004. Insulin resistance syndrome, pre-diabetes, and the prevention of type 2 diabetes mellitus. Clin. Cornerstone 6(2):7-13.
24. Biessels, G.-J., E. ter Braak, D. Erkelens, and R. Hijman. 2001. Cognitive function in patients with type 2 diabetes mellitus. Neurosci. Res. Commun. 28(1):11-22.
25. Akisaki, T., T. Sakurai, T. Takata, H. Umegaki, A. Araki, S. Mizuno, S. Tanaka, Y. Ohashi, A. Iguchi, K. Yokono, and H. Ito. 2006. Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab. Res. Rev. 22(5):376-384.
26. Strachan, M., I. Deary, F. Ewing, and B. Frier. 1997. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20(3):438-445.
27. Vanhanen, M., K. Koivisto, L. Karjalainen, E. L. Helkala, M. Laakso, H. Soininen, and P. Riekkinen, Sr. 1997. Risk for non-insulin-dependent diabetes in the normoglycaemic elderly is associated with impaired cognitive function. NeuroReport. 8(6):1527-1530.
28. Convit, A. 2005. Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol. Aging 26(1, Supplement 1):31-35 (Dec).
29. Gold, S. M., I. Dziobek, V. Sweat, A. Tirsi, K. Rogers, H. Bruehl, W. Tsui, S. Richardson, E. Javier, and A. Convit. 2007. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 50(4):711-719.
30. Convit, A., O. T. Wolf, C. Tarshish, and M. J. de Leon. 2003. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc. Natl. Acad. Sci. U. S. A. 100(4):2019-2022.
31. Gunstad, J., R. H. Paul, R. A. Cohen, D. F. Tate, M. B. Spitznagel, and E. Gordon. 2007. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr. Psychiatry 48(1):57-61.
32. Weisell, R. C. 2002. Body mass index as an indicator of obesity. Asia Pac. J. Clin. Nutr. 11(Suppl 8):S681-S684.
33. Jeong, S. K., H. S. Nam, M. H. Son, E. J. Son, and K. H. Cho. 2005. Interactive effect of obesity indexes on cognition. Dement. Geriatr. Cogn. Disord. 19(2-3):91-96.
34. Elias, M. F., P. K. Elias, L. M. Sullivan, P. A. Wolf, and R. B. D'Agostino. 2005. Obesity, diabetes and cognitive deficit: the Framingham Heart Study. Neurobiol. Aging 26(1, Supplement 1):11-16 (Dec).
35. Cournot, M., J. C. Marquie, D. Ansiau, C. Martinaud, H. Fonds, J. Ferrieres, and J. B. Ruidavets. 2006. Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurol. 67(7):1208-1214 (Oct).
36. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19):2486-2497 (May).
37. Komulainen, P., T. A. Lakka, M. Kivipelto, M. Hassinen, E. L. Helkala, I. Haapala, A. Nissinen, and R. Rauramaa. 2007. Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women. Dement. Geriatr. Cogn. Disord. 23(1):29-34.
38. Yaffe, K., A. Kanaya, K. Lindquist, E. M. Simonsick, T. Harris, R. I. Shorr, F. A. Tylavsky, and A. B. Newman. 2004. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292(18):2237-2242 (Nov).
39. Dik, M. G., C. Jonker, H. C. Comijs, D. J. Deeg, A. Kok, K. Yaffe, and B. W. Penninx. 2007. Contribution of metabolic syndrome components to cognition in older persons. Diabetes Care 30:2655-2660 (Jun).
40. Kuo, H. K., C. J. Yen, C. H. Chang, C. K. Kuo, J. H. Chen, and F. Sorond. 2005. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 4(6):371-380 (Jun).
41. Bruehl, H., M. Rueger, I. Dziobek, V. Sweat, A. Tirsi, E. Javier, A. Arentoft, O. T. Wolf, and A. Convit. 2007. Hypothalamic-pituitary-adrenal axis dysregulation and memory impairments in Type 2 diabetes. J. Clin. Endocrinol. Metab. 92(7):2439-2445 (Jul).
42. Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. J. Am. Diet Assoc. 98(10):1178-1191 (Oct).
43. Raz, N., K. M. Rodrigue, and J. D. Acker. 2003. Hypertension and the brain: vulnerability of the prefrontal regions and executive functions. Behav. Neurosci. 117(6):1169-1180 (Dec).
44. Lezak, M. D. 1995. Neuropsychological Assessment. 3rd ed. Oxford University Press, New York.
45. Hamilton, M. 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23:56-62.
46. Ansell, B., K. Watson, R. Weiss, and G. Fonarow. 2003. hsCRP and HDL Effects of Statins Trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. Heart Dis. 5:2-7.
47. Hanefeld, M., N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst. 2007. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J. Am. Coll. Cardiol. 49(3):290-297 (Jan).
48. Kinlay, S. 2007. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein. J. Am. Coll. Cardiol. 49(20):2003-2009.
49. Kritchevsky, S. B., M. Cesari, and M. Pahor. 2005. Inflammatory markers and cardiovascular health in older adults. Cardiovasc. Res. 66(2):265-275 (May).
50. Neisser, U., G. Boodoo, T. J. Bouchard, A. W. Boykin, N. Brody, S. J. Ceci, D. F. Halpern, J. C. Loehlin, R. Perloff, R. J. Sternberg, and S. Urbina. 1996. Intelligence: knowns and unknowns. Am. Psychol. 51(2):77-101 (Feb).
51. Barzilai, N., G. Atzmon, C. A. Derby, J. M. Bauman, and R. B. Lipton. 2006. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurol. 67:2170-2175.
52. Ramlawi, B., J. L. Rudolph, S. Mieno, J. Feng, M. Boodhwani, K. Khabbaz, S. E. Levkoff, E. R. Marcantonio, C. Bianchi, and F. W. Sellke. 2006. C-reactive protein and inflammatory response associated to neurocognitive decline following cardiac surgery. Surgery 140(2):221-226 (Aug).
53. Mathew, J. P., M. V. Podgoreanu, H. P. Grocott, W. D. White, R. W. Morris, M. Stafford-Smith, G. B. Mackensen, C. S. Rinder, J. A. Blumenthal, D. A. Schwinn, and M. F. Newman. 2007. Genetic variants in P-selectin and C-reactive protein influence susceptibility to cognitive decline after cardiac surgery. J. Am. Coll. Cardiol. 49(19):1934-1942 (May).
54. de Luca, C., and J. M. Olefsky. 2006. Stressed out about obesity and insulin resistance. Nat. Med. 12(1):41-42 (Jan).
55. Johnson, J. L., C. A. Slentz, B. D. Duscha, G. P. Samsa, J. S. McCartney, J. A. Houmard, and W. E. Kraus. 2004. Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study. Atherosclerosis 176(2):371-377 (Oct).
56. Abdullah, S. M., A. Khera, D. Leonard, S. R. Das, R. M. Canham, S. A. Kamath, G. L. Vega, S. M. Grundy, D. K. McGuire, and J. A. de LemosSex differences in the association between leptin and CRP: results from the Dallas Heart Study. Atherosclerosis 195(2):404-410.
57. Molina, M. J., A. M. Mayor, A. E. Franco, C. A. Morell, M. A. Lopez, and L. M. Vila. 2007. Prevalence of systemic lupus erythematosus and associated comorbidities in Puerto Rico. J. Clin. Rheumatol. 13(4):202-204 (Aug).
58. Racial/ethnic differences in the prevalence and impact of doctor-diagnosed arthritis-United States, 2002. MMWR Morb Mortal Wkly Rep. 54(5):119-123 (Feb).
59. Linares, L. F., J. J. Gomez-Reino, P. E. Carreira, L. Morillas, and I. Ibero. 1986. C-reactive protein (CRP) levels in systemic lupus erythematosus (SLE). Clin. Rheumatol. 5(1):66-69 (Jan).
60. Popkova, T. V., A. N. Khelkovskaia, E. S. Mach, E. N. Aleksandrova, A. A. Novikov, D. S. Novikova, and E. L. Nasonov. 2007. Cardiovascular diseases in rheumatoid arthritis. Ter. Arkh. 79(5):9-14.
61. Urowitz, M. B., and D. D. Gladman. 2007. Atherosclerosis and lupus-the SLICC study. Lupus. 16(12):925-928.
62. Assous, N., E. Touze, C. Meune, A. Kahan, and Y. Allanore. 2007. Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France. Jt. Bone Spine 74(1):66-72 (Jan).
63. Shucard, J. L., J. J. Gaines, J. Ambrus Jr., and D. W. Shucard. 2007. C-reactive protein and cognitive deficits in systemic lupus erythematosus. Cogn. Behav. Neurol. 20(1):31-37 (Mar).
64. Nandula, S. R., S. Amarnath, A. Molinolo, B. C. Bandyopadhyay, B. Hall, C. M. Goldsmith, C. Zheng, J. Larsson, T. Sreenath, W. Chen, I. S. Ambudkar, S. Karlsson, B. J. Baum, and A. B. Kulkarni. 2007. Female mice are more susceptible to developing inflammatory disorders due to impaired transforming growth factor beta signaling in salivary glands. Arthritis Rheum. 56(6):1798-1805 (Jun).
65. Pradhan, A. D., J. E. Manson, J. E. Rossouw, D. S. Siscovick, C. P. Mouton, N. Rifai, R. B. Wallace, R. D. Jackson, M. B. Pettinger, and P. M. Ridker. 2002. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288(8):980-987 (Aug).
66. Singh, U., S. Devaraj, J. Vasquez-Vivar, and I. Jialal. 2007. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J. Mol. Cell Cardiol. 43(6):780-791 (Dec).
67. Jialal, I., S. Devaraj, and S. K. Venugopal. 2004. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44(1):6-11 (Jul).
68. Verma, S., C. H. Wang, S. H. Li, A. S. Dumont, P. W. Fedak, M. V. Badiwala, B. Dhillon, R. D. Weisel, R. K. Li, D. A. Mickle, and D. J. Stewart. 2002. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106(8):913-919 (Aug).
69. Schmidt, R., C. Enzinger, S. Ropele, H. Schmidt, and F. Fazekas. 2006. Subcortical vascular cognitive impairment: Similarities and differences with multiple sclerosis. J. Neurol. Sci. 245(1-2):3-7 (Jun).
70. Gold, S. M., I. Dziobek, K. Rogers, A. Bayoumy, P. F. McHugh, and A. Convit. 2005. Hypertension and hypothalamo-pituitary-adrenal axis hyperactivity affect frontal lobe integrity. J. Clin. Endocrinol. Metab. 90(6):3262-3267 (Jun).
71. Raz, N., K. M. Rodrigue, and J. D. Acker. 2003. Hypertension and the brain: vulnerability of the prefrontal regions and executive functions. Behav. Neurosci. 117(6):1169-1180 (Dec).
72. van Dijk, E. J., N. D. Prins, S. E. Vermeer, H. A. Vrooman, A. Hofman, P. J. Koudstaal, and M. M. B. Breteler. 2005. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 112(6):900-905 (Aug).